Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Diabetes Mellitus, Type 2
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Show an increase in markers of ER stress in fasting patients with type 2 diabetes
- Last Updated
- 10 years ago
Overview
Brief Summary
The purpose of this study is to investigate whether Endoplasmic Reticulum (ER) stress pathway is activated in peripheral tissues (adipose tissue) in insulin resistant diabetic patients compared to healthy subjects normoglycemic matched for age and sex an to investigate whether ER stress pathway can be activated in response to insulin. Indeed, some preliminar on rates studies shows that ER stress pathway is activated by insulin in liver and adipose tissue showing that hyperinsulinemia might help trigger stress path ER.
For this, we propose a case control study of type 2 diabetic patients vs control subjects in which markers of ER stress will be evaluated from abdominal subcutaneous adipose tissue obtained before and after euglycemic hyperinsulinemic. We chose to consider adipose tissue subcutaneous rather than visceral adipose tissue for obvious reasons of lesser invasiveness.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Specific criteria for diabetic patients:
- •Having type 2 diabetes for at least 6 months
- •HbA1c ≤ 8%
- •Treated by lifestyle and dietary rules associated or not to a hypoglycemic therapy (metformin and / or sulfamid) and / or insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4): Vildagliptin, Sitagliptin, Saxagliptin
- •No modification of hypoglycemic therapy and / or insulin secretors for at least 3 months
- •Specific criteria for control subjects:
- •Nondiabetic subjects (fasting blood glucose \<7.0 mmol / l without hypoglycemic treatment).
- •The control subjects should be matched to patients for age (± 5 years), sex, and BMI (± 2 kg/m2).
- •Common criteria for patients and control subjects:
- •Aged 18 to 60 years
Exclusion Criteria
- •Current infections or recent infections (\<10 days)
- •Neoplastic disorders (with the exception of carcinoma in situ of the cervix or cutaneous epithelioma), haematological, cardiovascular, psychiatric, neurological
- •Poisoning smoking (\>10 cigarettes per day, what ever the duration of intoxication)
- •Treatment with insulin or glitazones Pregnancy, Breastfeeding
- •Body Mass Index \> 35 kg/m2
- •Any drug taken for less than 8 days without the inclusion of minor analgesics (aspirin, paracetamol), anti-hypertensive medications, oral hypoglycemic (metformin and sulphonylureas) and insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4) and oral contraceptives.
Outcomes
Primary Outcomes
Show an increase in markers of ER stress in fasting patients with type 2 diabetes
Time Frame: 2 days
Protein expression markers of ER stress pathway BiP / GRP 78, CHOP, ATF4 EDEM and XBP-1
Secondary Outcomes
- Insulin secretion in response to arginine infusion(2 days)
- Assess whether insulin induces an increase in markers of ER stress(2 days)
- Insulin secretion in response to glucose infusion(2 days)
- Lipolysis on insulin(2 days)